Nov. 25, 2009 (PR Newswire) -- WHAT: The Lupus Foundation of America (LFA) invites those living with lupus to a special Webinar with LFA's Medical Director, Dr. Joan Merrill. Human Genome Sciences (HGSI) and GlaxoSmithKline (GSK) recently announced positive results for two Phase III clinical trials for BENLYSTA(TM), a potential new treatment for lupus. If approved by the U.S. Food and Drug Administration (FDA), BENLYSTA(TM) would be the first drug ever developed and approved specifically for the treatment of lupus, since the disease was discovered more than a century ago. Dr. Merrill will review the results, answer questions, and discuss its potential impact on patients.
WHO: People with lupus, those affected by lupus, and anyone interested in learning more about BENLYSTA(TM)
WHERE: Please note that space at the event is limited. The LFA will provide a summary of the discussion following the event for those who are unable to attend.
Call In Details
1. Dial the Conference Access Number: 212-401-6760 | 866-551-3680
2. Enter your Participant PIN Code followed by the # key: 7292757#
3. You will be placed on musical hold until the Event begins
4. To join the Web Conference click this link:
https://www.anywhereconference.com/?Conference=130257715&PIN=7292757
5. Enter your Name
6. Click Go
Or Join the Web Conference Manually
1. To join the Web Conference log into: https://www.anywhereconference.com/
2. Enter the Web Login Reference: 130257715
3. Enter the PIN Code: 7292757
4. Enter your Name
5. Click Go
WHEN: Monday, November 30, 2009
7:00 p.m. EST.
WHY: It has been 50 years since the FDA approved a drug for lupus. Current therapies have side effects that can be worse than the primary disease, including fatigue, joint pain, bone loss, osteoporosis, and increased risk of infection. If ultimately approved by the FDA, BENLYSTA(TM) could represent a breakthrough in lupus research, and a significant first step in developing the full arsenal of therapies and personalized treatment lupus requires.
Visit lupus.org for more information, or to submit an advanced question.
CONTACT: Maggie Maloney, Maloney@lupus.org, +1-202-212-6766
/PRNewswire-USNewswire -- Nov. 25/
SOURCE Lupus Foundation of America
